Virion is developing novel T cell-based immunotherapies for cancer and infectious diseases via a first-in-class genetically encoded checkpoint inhibitor (CPI) of early T cell activation. Following intramuscular injection, the immune responses produced are best-in-class with enhanced clinical responses in animal models. The unique mechanism of our CPI solves a number of key limitations of monoclonal antibody checkpoint inhibitor therapies and could provide access to larger patient populations and previously un-targetable disease states. Virion’s lead programs are for treatment of chronic Hepatitis B virus (CHBV) and cancers and persistent infections caused by Human Papillomavirus (HPV).
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
VRON-0200 Chronic Hepatitis B Virus
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):